These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9381703)

  • 1. [Biochemical parameters in the diagnosis of nephrotoxicity of antineoplastic chemotherapy in children].
    Liubimova NV; Kumykova ZhKh; Kushlinskiĭ NE; Kasumov ChM; Durnov LA
    Vopr Onkol; 1997; 43(4):448-53. PubMed ID: 9381703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
    J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
    Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
    Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
    Zielińska E; Zubowska M; Bodalski J
    Pol Merkur Lekarski; 2003 Apr; 14(82):295-8. PubMed ID: 12868187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glutamin concentrations in patients treated with cisplatin have a predicting value of renal failure development].
    Cobo M; Martín Gómez MA; Frutos MA; Benavides M
    Nefrologia; 2007; 27(1):23-9. PubMed ID: 17402876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of cisplatin-induced nephrotoxicity in rats by tetramethylpyrazine, a major constituent of the Chinese herb Ligusticum wallichi.
    Ali BH; Al-Moundhri M; Eldin MT; Nemmar A; Al-Siyabi S; Annamalai K
    Exp Biol Med (Maywood); 2008 Jul; 233(7):891-6. PubMed ID: 18445776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The kidney in children under chemotherapy].
    Cachat F; Guignard JP
    Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity.
    Aydinoz S; Uzun G; Cermik H; Atasoyu EM; Yildiz S; Karagoz B; Evrenkaya R
    Ren Fail; 2007; 29(3):257-63. PubMed ID: 17497437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ifosfamide induced encephalopathy: 15 observations].
    Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
    Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats.
    Atessahin A; Yilmaz S; Karahan I; Ceribasi AO; Karaoglu A
    Toxicology; 2005 Sep; 212(2-3):116-23. PubMed ID: 15946783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.